All nine pancreatic adenocarcinomas harbored exon 2 pathogenic gain‐of‐function variants in KRAS and 6/9 cases had a deleterious loss‐of‐function variant in TP53. This evidence concerns the gene TP53 and pancreatic adenocarcinoma.